Inari Medical, Inc. - NARI STOCK NEWS

Inari Medical, Inc. (NASDAQ: NARI), a medical device company specializing in treatments for venous diseases, announced its participation in two upcoming investor conferences. The first is the BTIG MedTech Conference on February 15, 2022, at 12:00 p.m. Eastern Time. The second is the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 1:00 p.m. Eastern Time, with a live audio webcast available. Inari develops innovative catheter-based devices for the non-surgical treatment of conditions like deep vein thrombosis and pulmonary embolism.

Inari Medical (NASDAQ: NARI) reported preliminary unaudited revenue for Q4 2021, indicating a range of $82.8 to $83.3 million, marking a 14% sequential and 71% year-over-year increase. For the full year 2021, revenue is expected between $276.6 and $277.1 million, representing an approximate 98% rise over 2020. The company treated 7,700 patients in Q4, a 15% increase from Q3. Inari continues to focus on non-COVID patients, with over 200 U.S. sales territories established.

Inari Medical, Inc. (NASDAQ: NARI) is set to present at the 40^th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 3:00 p.m. Eastern Time. The presentation will focus on the company's innovative products designed for treating venous diseases, emphasizing its minimally-invasive catheter-based mechanical thrombectomy devices. These devices, the ClotTriever and FlowTriever systems, are FDA-cleared and CE-marked for the removal of clots from peripheral blood vessels, specifically targeting conditions like deep vein thrombosis and pulmonary embolism.

Inari Medical (NASDAQ: NARI) reported a record revenue of $72.9 million for Q3 2021, marking a 15% sequential and 88% year-over-year increase. The FDA cleared the ClotTriever Bold Thrombectomy Catheter, expanding treatment options for patients with advanced DVT. The company's gross profit reached $65.9 million, yielding a gross margin of 90.3%. However, operating expenses surged to $68.6 million, primarily due to increased personnel costs and stock-based compensation. Inari's cash reserves stand at $168.6 million. The revenue guidance for 2021 was raised to $266 to $268 million.

Inari Medical, Inc. (NASDAQ: NARI) announced promising interim results from the FlowTriever Outcomes Registry (FLASH) involving 500 pulmonary embolism patients. At 48 hours post-procedure, the major adverse event rate was 1.4% and mortality rate a low 0.2%, with no device-related complications. Significant improvements were observed in cardiac function and quality of life at 6 months. The study highlights FlowTriever as a leading therapy for intermediate and high-risk PE patients, demonstrating safety and effectiveness while minimizing hospital resource use.

Inari Medical, Inc. (NASDAQ: NARI) announced it will release its third quarter financial results on November 9, 2021. A conference call and webcast will follow at 1:30 PM PT / 4:30 PM ET to discuss these results and recent highlights. Inari specializes in medical devices for treating venous diseases, featuring FDA-cleared systems such as ClotTriever for deep vein thrombosis and FlowTriever for pulmonary embolism. Interested parties can join the call through provided phone numbers or access the webcast via Inari's investor relations website.

Inari Medical, Inc. (NASDAQ: NARI) announced the upcoming enrollment of the PEERLESS trial, a pivotal randomized controlled trial comparing the FlowTriever System against catheter-directed thrombolysis for treating intermediate-high risk pulmonary embolism. The trial will include up to 700 patients at 60 centers across the U.S. and Europe. Key outcomes will focus on mortality, major bleeding events, and ICU stay duration. The PEERLESS trial aims to provide critical data to reshape treatment guidelines for venous thromboembolism.

Inari Medical, Inc. (NASDAQ: NARI) has appointed Mr. Dana G. Mead, Jr. to its board of directors, where he will also serve on the Compensation Committee. His extensive experience in leading high-growth medical technology companies is expected to be crucial as Inari advances its mission to treat venous thromboembolism. Mead's prior roles include President and CEO of HeartFlow, and he has held leadership positions at Beaver-Visitec and Guidant Corporation. Inari is known for its innovative catheter-based thrombectomy devices aimed at improving patient outcomes in venous diseases.

Inari Medical (NASDAQ: NARI) has appointed Dr. Victor F. Tapson as VP of Medical Affairs. Dr. Tapson brings extensive expertise in pulmonary diseases, particularly in pulmonary embolism and hypertension, and has authored over 200 peer-reviewed articles. His previous roles include establishing the first Pulmonary Embolism Response Team at Cedars-Sinai Medical Center and leading innovative programs at Duke University. Dr. Tapson's leadership is expected to enhance Inari's mission to improve venous disease treatments, specifically targeting venous thromboembolism (VTE).